B-MoGen Biotechnologies Inc
TcBuster transposon system for non-viral delivery of CAR and TCR genes into T cells for cancer immunotherapy
- Sector
- Biotech
- Headquarters
- ST. PAUL, MN
- Founded
- 2015
- Latest Form D
- $1M, May 2016
- Total capital
- $3.3M
- Federal grants
- $2.2M
- 6 awards · 2017–2019
- Rank in peer group#308 of 392
- Private capital raised
- $1M
- 1 Form D · last May 2016
- 125 months since last filing
- Federal contracts
- $100K
- 1 award · Interior
- Rank in Biotech#331 of 4373
- Granted patents
- 5
- 6 pending · first 2019
- Rank in peer group#25 of 392
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Rapid Non-Viral Platform for Generation of Genetically Modified T Cells for Therapy$1.1M
- Federal grantHealth and Human S · Phase I · Development of mitochondrial disease mouse models$225K
- Federal grantHealth and Human S · Phase I · Development of mitochondrial disease mouse models$225K
- Federal grantHealth and Human S · Phase II · Rapid Non-Viral Platform for Generation of Genetically Modified T Cells for Therapy$219K
- Federal grantHealth and Human S · Phase I · Effective engineering of the mitochondrial genome$225K
- Federal contractInterior · Igf::ot::igf Next Generation Genome Editing Tools$100K
- Federal grantHealth and Human S · Phase I · Stable Gene Transfer by RNA Delivery$225K
- Private capital raisedForm D · SEC · 1st filing$1M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 392 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#25 · top 6%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- David LargaespadaResearcherDirectorLinked by 5 patents
- Branden MoriarityDirectorNamed in SEC Form D filings
- Jeff LiterExecutive Officer, DirectorNamed in SEC Form D filings
- Kristin GeislerExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 5 granted of 11- GrantedENHANCED hAT FAMILY TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODSUSPTOUS 11,760,983
- GrantedENHANCED hAT FAMILY TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODSUSPTOUS 11,278,570
- GrantedEnhanced hAT Family Transposon-Mediated Gene Transfer and Associated Compositions, Systems, and MethodsUSPTOUS 11,162,084
Show all 11 patent records
- ENHANCED hAT FAMILY TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODSSep 19, 2023 · US 11,760,983Granted
- ENHANCED hAT FAMILY TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODSMar 22, 2022 · US 11,278,570Granted
- Enhanced hAT Family Transposon-Mediated Gene Transfer and Associated Compositions, Systems, and MethodsNov 2, 2021 · US 11,162,084Granted
- Enhanced Hat Family Transposon-mediated Gene Transfer And Associated Compositions, Systems And MethodsSep 7, 2021 · US 11,111,483Granted
- ENHANCED hAT FAMILY TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODSMar 12, 2019 · US 10,227,574Granted
- Enhanced hAT Family Transposon-Mediated Gene Transfer and Associated Compositions, Systems, and MethodsAug 30, 2018 · Application 15958834Pending
- Enhanced Hat Family Transposon-mediated Gene Transfer And Associated Compositions, Systems, And MethodsApplication PCTUS2017066829Pending
- ENHANCED hAT FAMILY SPIN TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODSApplication 63035441Pending
- Enhanced Hat Family Transposon-mediated Gene Transfer And Associated Compositions, Systems, And MethodsApplication PCTUS2019038410Pending
- ENHANCED hAT FAMILY TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODSApplication 62688278Pending
- Enhanced Hat Family Member Spin Transposon-mediated Gene Transfer And Associated Compositions, Systems, And MethodsApplication PCTUS2021035888Pending
Related companies, and why
- CARRYGENES BIOENGINEERING, LLCSimilar federal contract value in Biotech · $101K in contracts
- EXEMPLAR GENETICS, LLCSimilar federal contract value in Biotech · $101K in contracts
- SYNZYME TECHNOLOGIES LLCSimilar federal contract value in Biotech · $100K in contracts
- ADVAITA CORPSimilar federal contract value in Biotech · $97K in contracts
- Data2Discovery IncSimilar federal contract value in Biotech · $97K in contracts
- FLUENT BIOSCIENCES INCSimilar federal contract value in Biotech · $96K in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .